Current trends in oncology trial terminations as analyzed by Citeline have revealed that sponsors are learning from the past and making gains in this troubled area of drug development.
Christine Blazynski, Ph.D.
Advertisement
Senior Vice-President, Product Development Citeline
Articles by Christine Blazynski, Ph.D.
Advertisement
Latest Updated Articles
Trends in Oncology Trial Terminations: Industry Lessons LearnedPublished: August 23rd 2012 | Updated:
- Hidden Successes of Oncology Trial Terminations
Published: October 1st 2012 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Establishing Governance for No-Code AI in Clinical Operations
2
Applied Clinical Trials' 2025 State of the Industry Survey
3
Do Phase II Protocol Learnings Help Simplify Phase III Protocol Designs?
4
The Confidence Trap in Clinical Trials: When Knowing Just Enough Becomes Dangerous
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
